-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Benzinga·07/21/2026 13:33:24
Listen to the news
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.